首页 > 最新文献

Acta Poloniae Pharmaceutica - Drug Research最新文献

英文 中文
Novel CDK4/6 lnhibitor, WXJ-8 -Exerts Anti-effects Through Cell Cycle in Breast Cancer 新型 CDK4/6 抑制剂 WXJ-8 通过细胞周期对乳腺癌发挥抗癌作用
Pub Date : 2023-11-22 DOI: 10.32383/appdr/173986
Jing Ji, Zhen Zhang, Guanrong Li, Lingyi Zuo, JIAO-JIAO Zhou, Xiu-jun Wang, SHAO-JIE Ma, Bin Liu, JIN-QING Han, Xiao Hou
The novel Abemaciclib derivative WXJ-8 may be a promising anti-tumour drug; however, its mechanism of action and clinical value need to be further verified in research. Cell cycle regulating systems are critical in parthenogenesis and progression. Because of its involvement in regulating cell cycle checkpoints, the CDK4/6-CyclinD1-Rb-E2F1 signalling pathway has been proposed as a possible therapeutic target for breast cancer. As a result, WXJ-8, a new and highly specific CDK4/6 inhibitor, was developed and synthesized in this investigation. The activity of WXJ-8 against breast cancer cells in vitro was detected by MTT method. The main subjects were MDA-MB-231 and MCF-7 cells. Plate cloning, wound healing, invasion and adhesion experiments revealed that WXJ-8 had strong anti-proliferation, migration, invasion, and adhesion effects on breast cancer cells. Protein blotting revealed significant down regulation of CDK4, CDK6, p-Rb, E2F1 and other cell cycle factors in the CDK4/6-CyclinD1-Rb-E2F1 pathway, as well as activation of Bcl-2, Caspase-3, and Cleaved Caspase-3 apoptotic factor expression, resulting in MDA-MB-231 cell cycle arrest and apoptosis. Finally, our research implies that WXJ-8 might be a potential anti-triple-negative breast cancer medication candidate.
新型 Abemaciclib 衍生物 WXJ-8 可能是一种很有前景的抗肿瘤药物,但其作用机制和临床价值还需要进一步研究验证。细胞周期调节系统在孤雌生殖和发育过程中至关重要。由于 CDK4/6-CyclinD1-Rb-E2F1 信号通路参与调节细胞周期检查点,因此被认为是乳腺癌的可能治疗靶点。因此,本研究开发并合成了一种新型高特异性 CDK4/6 抑制剂 WXJ-8。WXJ-8 对乳腺癌细胞的体外活性采用 MTT 法进行检测。主要研究对象为 MDA-MB-231 和 MCF-7 细胞。平板克隆、伤口愈合、侵袭和粘附实验表明,WXJ-8 对乳腺癌细胞具有很强的抗增殖、抗迁移、抗侵袭和抗粘附作用。蛋白质印迹显示,CDK4、CDK6、p-Rb、E2F1 和 CDK4/6-CyclinD1-Rb-E2F1 通路中的其他细胞周期因子表达明显下调,Bcl-2、Caspase-3 和裂解 Caspase-3 凋亡因子表达被激活,从而导致 MDA-MB-231 细胞周期停滞和凋亡。最后,我们的研究表明,WXJ-8可能是一种潜在的抗三阴性乳腺癌候选药物。
{"title":"Novel CDK4/6 lnhibitor, WXJ-8 -Exerts Anti-effects Through Cell Cycle in Breast Cancer","authors":"Jing Ji, Zhen Zhang, Guanrong Li, Lingyi Zuo, JIAO-JIAO Zhou, Xiu-jun Wang, SHAO-JIE Ma, Bin Liu, JIN-QING Han, Xiao Hou","doi":"10.32383/appdr/173986","DOIUrl":"https://doi.org/10.32383/appdr/173986","url":null,"abstract":"The novel Abemaciclib derivative WXJ-8 may be a promising anti-tumour drug; however, its mechanism of action and clinical value need to be further verified in research. Cell cycle regulating systems are critical in parthenogenesis and progression. Because of its involvement in regulating cell cycle checkpoints, the CDK4/6-CyclinD1-Rb-E2F1 signalling pathway has been proposed as a possible therapeutic target for breast cancer. As a result, WXJ-8, a new and highly specific CDK4/6 inhibitor, was developed and synthesized in this investigation. The activity of WXJ-8 against breast cancer cells in vitro was detected by MTT method. The main subjects were MDA-MB-231 and MCF-7 cells. Plate cloning, wound healing, invasion and adhesion experiments revealed that WXJ-8 had strong anti-proliferation, migration, invasion, and adhesion effects on breast cancer cells. Protein blotting revealed significant down regulation of CDK4, CDK6, p-Rb, E2F1 and other cell cycle factors in the CDK4/6-CyclinD1-Rb-E2F1 pathway, as well as activation of Bcl-2, Caspase-3, and Cleaved Caspase-3 apoptotic factor expression, resulting in MDA-MB-231 cell cycle arrest and apoptosis. Finally, our research implies that WXJ-8 might be a potential anti-triple-negative breast cancer medication candidate.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139249774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis, Antiviral and Cytostatic Activity of New Series of Naphthalimide Derivatives 新系列萘啶酰亚胺衍生物的合成、抗病毒和细胞抑制活性
Pub Date : 2023-11-21 DOI: 10.32383/appdr/171434
Katarzyna Gawron, D. Piotrowska, G. Andrei, D. Schols, R. Snoeck, I. Głowacka
A new series of N-(diethylphosphonoalkyl)-1,8-naphthalimides were synthesized via direct reaction of 1,8-naphthalic anhydride or its 3-nitro- and 4-bromo- derivatives with selected ɷ-aminoalkylphosphonates and evaluated against a broad-spectrum of viruses as well as for their cytostatic properties toward selected cell lines. N-(diethylphosphonomethyl)-3-nitro-1,8-naphthalimide 15a exhibited inhibitory activity toward coxsackie virus B4 in Vero cells (EC50 = 9.45 μM), whereas 3-nitro-1,8-naphthalimides 15b and 15d containing short 2-carbon linker showed moderate activity against herpes simplex virus-2 (G) and herpes simplex virus-1 TK– KOS ACVr. Furthermore, compounds 15a, 15b and 15d showed antiviral potency against human coronavirus. Several naphthalimides exhibited cytostatic activity toward tested cancerous cell lines as well as normal retina cells. Transformation of selected diethyl phosphonates 13, 14 and 15 into ammonium phosphonates 21, 22 and 23 improved the solubility, however, did not result in the enhancement of antiviral and cytostatic potency of the compounds.
通过 1,8-萘二甲酸酐或其 3-硝基和 4-溴衍生物与选定的ɷ-氨基烷基膦酸盐直接反应,合成了一系列新的 N-(二乙基膦酰基)-1,8-萘二甲酰亚胺,并评估了它们对广谱病毒的抑制作用以及对选定细胞系的细胞抑制特性。N-(二乙基膦酰甲基)-3-硝基-1,8-萘二甲酰亚胺 15a 在 Vero 细胞中对柯萨奇病毒 B4 具有抑制活性(EC50 = 9.45 μM),而含有短 2 碳连接体的 3-硝基-1,8-萘二甲酰亚胺 15b 和 15d 对单纯疱疹病毒-2(G)和单纯疱疹病毒-1 TK- KOS ACVr 具有中等程度的活性。此外,化合物 15a、15b 和 15d 对人类冠状病毒具有抗病毒效力。一些萘二甲酰亚胺化合物对测试的癌细胞系和正常视网膜细胞具有细胞抑制活性。将选定的膦酸二乙酯 13、14 和 15 转化为膦酸铵 21、22 和 23 可以提高溶解度,但并不能增强化合物的抗病毒和细胞抑制效力。
{"title":"Synthesis, Antiviral and Cytostatic Activity of New Series of Naphthalimide Derivatives","authors":"Katarzyna Gawron, D. Piotrowska, G. Andrei, D. Schols, R. Snoeck, I. Głowacka","doi":"10.32383/appdr/171434","DOIUrl":"https://doi.org/10.32383/appdr/171434","url":null,"abstract":"A new series of N-(diethylphosphonoalkyl)-1,8-naphthalimides were synthesized via direct reaction of 1,8-naphthalic anhydride or its 3-nitro- and 4-bromo- derivatives with selected ɷ-aminoalkylphosphonates and evaluated against a broad-spectrum of viruses as well as for their cytostatic properties toward selected cell lines. N-(diethylphosphonomethyl)-3-nitro-1,8-naphthalimide 15a exhibited inhibitory activity toward coxsackie virus B4 in Vero cells (EC50 = 9.45 μM), whereas 3-nitro-1,8-naphthalimides 15b and 15d containing short 2-carbon linker showed moderate activity against herpes simplex virus-2 (G) and herpes simplex virus-1 TK– KOS ACVr. Furthermore, compounds 15a, 15b and 15d showed antiviral potency against human coronavirus. Several naphthalimides exhibited cytostatic activity toward tested cancerous cell lines as well as normal retina cells. Transformation of selected diethyl phosphonates 13, 14 and 15 into ammonium phosphonates 21, 22 and 23 improved the solubility, however, did not result in the enhancement of antiviral and cytostatic potency of the compounds.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139252063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polycystic Ovary Syndrome (PCOS) - The Application of Selected off-label drugs found in medical databases 多囊卵巢综合症 (PCOS) - 医学数据库中发现的部分标签外药物的应用
Pub Date : 2023-11-21 DOI: 10.32383/appdr/172065
K. Kus, Maria Sygit, Maciuszek-Bartkowska Barbara, P. Ratajczak, A. Paczkowska, Dorota Kopciuch, T. Zaprutko
Medical databases are crucial tools in medicine and pharmacy, aiding studies on the impact of medical products on health and informing treatment decisions. However, prescribers must blend database insights with clinical expertise for accurate choices. Clinical experience doesn't always align with drug Summaries of Product Characteristics (SPCs). While SPC guidelines ensure safety, they might not optimize efficacy. For instance, treating Polycystic Ovary Syndrome (PCOS) often benefits from off-label therapies that are clinically and cost-effective. The study aimed to identify potential PCOS treatments beyond approved uses in Poland and globally. The methodology involved reviewing databases used by medical professionals. Out of 29, 11 databases were chosen based on off-label drug availability and relevance to PCOS. Results show that medical databases aid medical professionals in finding off-label PCOS treatments. These databases also assess a drug's potential efficacy and risks. However, their usefulness has limits, lacking comprehensive data on usage, mechanisms, and safety. When using literary databases, keyword selection significantly influences search results.
医学数据库是医学和药学领域的重要工具,有助于研究医疗产品对健康的影响,并为治疗决策提供信息。然而,处方者必须将数据库的见解与临床专业知识相结合,才能做出准确的选择。临床经验并不总是与药品的《产品特征概要》(SPC)一致。虽然 SPC 指南能确保安全性,但可能无法优化疗效。例如,治疗多囊卵巢综合症(PCOS)通常可以从临床和成本效益高的标签外疗法中获益。这项研究旨在确定波兰和全球范围内已获批准用途之外的潜在多囊卵巢综合症治疗方法。研究方法包括审查医疗专业人员使用的数据库。在 29 个数据库中,根据标示外药物的可用性和与多囊卵巢综合症的相关性选择了 11 个数据库。结果表明,医疗数据库有助于医疗专业人员找到标示外的多囊卵巢综合症治疗方法。这些数据库还能评估药物的潜在疗效和风险。然而,它们的作用也有局限性,缺乏有关用法、机制和安全性的全面数据。在使用文学数据库时,关键词的选择对搜索结果有很大影响。
{"title":"Polycystic Ovary Syndrome (PCOS) - The Application of Selected off-label drugs found in medical databases","authors":"K. Kus, Maria Sygit, Maciuszek-Bartkowska Barbara, P. Ratajczak, A. Paczkowska, Dorota Kopciuch, T. Zaprutko","doi":"10.32383/appdr/172065","DOIUrl":"https://doi.org/10.32383/appdr/172065","url":null,"abstract":"Medical databases are crucial tools in medicine and pharmacy, aiding studies on the impact of medical products on health and informing treatment decisions. However, prescribers must blend database insights with clinical expertise for accurate choices. Clinical experience doesn't always align with drug Summaries of Product Characteristics (SPCs). While SPC guidelines ensure safety, they might not optimize efficacy. For instance, treating Polycystic Ovary Syndrome (PCOS) often benefits from off-label therapies that are clinically and cost-effective. The study aimed to identify potential PCOS treatments beyond approved uses in Poland and globally. The methodology involved reviewing databases used by medical professionals. Out of 29, 11 databases were chosen based on off-label drug availability and relevance to PCOS. Results show that medical databases aid medical professionals in finding off-label PCOS treatments. These databases also assess a drug's potential efficacy and risks. However, their usefulness has limits, lacking comprehensive data on usage, mechanisms, and safety. When using literary databases, keyword selection significantly influences search results.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139253803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis and Verification of a Novel Attainable Tumor Targeting Magnetic Nanoparticle 合成并验证可实现肿瘤靶向的新型磁性纳米粒子
Pub Date : 2023-11-21 DOI: 10.32383/appdr/173984
Yingxiu Chen, Jiasheng Yan
This study aimed to prepare a novel multifunctional magnetic nanoparticle (MNP) with a drug-loadable encapsulation and a matrix metalloproteinase (MMP) substrate-modified TAT peptide whose transmembrane ability can be activated in an MMP-rich environment, and to evaluate the uptake of this nanoparticle by cells, as well as its cytotoxicity. Nanoparticles were synthesized and modified with TAT or MMPs-TAT peptides. PC-3 cells and RWPE-1 cells were cultured with these nanoparticles at different concentrations, with or without MMP-2 pretreatment, and their uptake rate and toxicity were determined using flow cytometry and fluorescence microscopy. The nanoparticles were characterized with TEM (transmission electron microscopy) and DLS (dynamic light scattering). The diameter of these nanoparticles ranged from 194.5 ± 69.4 nm to 353.1 ± 103.9 nm, which were in the ideal range for application. The cellular uptake of MMPs-TAT-MNPs appeared similar to MNPs, but significantly increased in the presence of MMP-2 pretreatment. MMPs-TAT-MNPs had no significant cytotoxicity at the concentration of ≤25 μg/ml. MMPs-TAT-MNPs with MMP-2 substrate modified TAT peptide is successfully prepared, possess a low cytotoxicity loadable cargo and can be activated in an MMP-2 rich niche.
本研究旨在制备一种新型多功能磁性纳米粒子(MNP),该纳米粒子具有药物负载包囊和基质金属蛋白酶(MMP)底物修饰的TAT肽,其跨膜能力可在富含MMP的环境中被激活,并评估细胞对这种纳米粒子的吸收及其细胞毒性。研究人员合成了纳米颗粒,并用 TAT 或 MMPs-TAT 肽对其进行修饰。PC-3 细胞和 RWPE-1 细胞在有或没有 MMP-2 预处理的情况下培养了不同浓度的纳米颗粒,并使用流式细胞仪和荧光显微镜测定了它们的吸收率和毒性。用 TEM(透射电子显微镜)和 DLS(动态光散射)对纳米颗粒进行了表征。这些纳米颗粒的直径在 194.5 ± 69.4 nm 到 353.1 ± 103.9 nm 之间,处于理想的应用范围。细胞对 MMPs-TAT-MNPs 的吸收与 MNPs 相似,但在 MMP-2 预处理的情况下会显著增加。MMPs-TAT-MNPs 在浓度≤25 μg/ml 时没有明显的细胞毒性。含 MMP-2 底物修饰 TAT 肽的 MMPs-TAT-MNPs 制备成功,具有低细胞毒性的可负载货物,并可在富含 MMP-2 的生态位中激活。
{"title":"Synthesis and Verification of a Novel Attainable Tumor Targeting Magnetic Nanoparticle","authors":"Yingxiu Chen, Jiasheng Yan","doi":"10.32383/appdr/173984","DOIUrl":"https://doi.org/10.32383/appdr/173984","url":null,"abstract":"This study aimed to prepare a novel multifunctional magnetic nanoparticle (MNP) with a drug-loadable encapsulation and a matrix metalloproteinase (MMP) substrate-modified TAT peptide whose transmembrane ability can be activated in an MMP-rich environment, and to evaluate the uptake of this nanoparticle by cells, as well as its cytotoxicity. Nanoparticles were synthesized and modified with TAT or MMPs-TAT peptides. PC-3 cells and RWPE-1 cells were cultured with these nanoparticles at different concentrations, with or without MMP-2 pretreatment, and their uptake rate and toxicity were determined using flow cytometry and fluorescence microscopy. The nanoparticles were characterized with TEM (transmission electron microscopy) and DLS (dynamic light scattering). The diameter of these nanoparticles ranged from 194.5 ± 69.4 nm to 353.1 ± 103.9 nm, which were in the ideal range for application. The cellular uptake of MMPs-TAT-MNPs appeared similar to MNPs, but significantly increased in the presence of MMP-2 pretreatment. MMPs-TAT-MNPs had no significant cytotoxicity at the concentration of ≤25 μg/ml. MMPs-TAT-MNPs with MMP-2 substrate modified TAT peptide is successfully prepared, possess a low cytotoxicity loadable cargo and can be activated in an MMP-2 rich niche.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139252930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stability of API as a Key Parameter for New Formulations Development - A Case Study of Rosuvastatin Calcium 作为新制剂开发关键参数的原料药稳定性--瑞舒伐他汀钙的案例研究
Pub Date : 2023-11-21 DOI: 10.32383/appdr/174028
Szymon Sip, P. Zalewski, J. Cielecka‐Piontek, Anna Pałubicka
This study investigated the degradation kinetics and stability of rosuvastatin calcium (RSV) in acidic and alkaline solutions at two different doses, 5 mg and 10 mg. The degradation reaction was characterised by the activation energy (Ea), enthalpy change (ΔH≠a), and entropy change (ΔS≠a). The degradation of RSV in acidic solution followed pseudo-first-order kinetics, with observed rate constants (kobs) of 2.63×10-3 s-1 and 3.80×10-3 s-1 for the 5 mg and 10 mg doses, respectively. The activation energy (Ea) was 102.1 kJ/mol and 101.8 kJ/mol for the 5 mg and 10 mg doses, respectively, indicating that the degradation process is moderately sensitive to temperature. The enthalpy change (ΔH≠a) for both doses was positive, with values of 92 kJ/mol and 102 kJ/mol for the 5 mg and 10 mg doses, respectively, indicating that the degradation reaction is endothermic, with the 5 mg dose requiring more significant heat input. The entropy change (ΔS≠a) for both doses was negative, with values of -0.219 kJ/(mol∙K) and -0.236 kJ/(mol∙K) for the 5 mg and 10 mg doses, respectively, indicating that the degradation process decreases the system's disorder, with the 5 mg dose having a more significant impact. The degradation of RSV in an alkaline medium was found to be a pseudo-first-order reaction, with observed rate constants ranging from 1.98×10-3 s-1 to 7.09×10-3 s-1, depending on the RSV concentration. The results suggest that higher RSV concentrations improve stability in alkaline conditions. These findings provide valuable insights into the stability of RSV under different pH conditions.
本研究探讨了罗苏伐他汀钙 (RSV) 在 5 毫克和 10 毫克两种不同剂量的酸性和碱性溶液中的降解动力学和稳定性。降解反应的特征是活化能(Ea)、焓变(ΔH≠a)和熵变(ΔS≠a)。RSV 在酸性溶液中的降解遵循伪一阶动力学,观察到 5 毫克和 10 毫克剂量的速率常数(kobs)分别为 2.63×10-3 s-1 和 3.80×10-3 s-1。5 毫克和 10 毫克剂量的活化能(Ea)分别为 102.1 kJ/mol 和 101.8 kJ/mol,表明降解过程对温度适度敏感。两种剂量的焓变(ΔH≠a)均为正值,5 毫克和 10 毫克剂量的焓变值分别为 92 kJ/mol 和 102 kJ/mol,表明降解反应是内热反应,其中 5 毫克剂量需要更多的热量输入。两种剂量的熵变 (ΔS≠a)均为负值,5 毫克和 10 毫克剂量的熵变值分别为-0.219 kJ/(mol∙K) 和-0.236 kJ/(mol∙K),表明降解过程降低了系统的无序性,其中 5 毫克剂量的影响更大。研究发现,RSV 在碱性介质中的降解是一种伪一阶反应,观察到的速率常数从 1.98×10-3 s-1 到 7.09×10-3 s-1 不等,这取决于 RSV 的浓度。结果表明,RSV 浓度越高,碱性条件下的稳定性越好。这些发现为了解 RSV 在不同 pH 值条件下的稳定性提供了宝贵的见解。
{"title":"Stability of API as a Key Parameter for New Formulations Development - A Case Study of Rosuvastatin Calcium","authors":"Szymon Sip, P. Zalewski, J. Cielecka‐Piontek, Anna Pałubicka","doi":"10.32383/appdr/174028","DOIUrl":"https://doi.org/10.32383/appdr/174028","url":null,"abstract":"This study investigated the degradation kinetics and stability of rosuvastatin calcium (RSV) in acidic and alkaline solutions at two different doses, 5 mg and 10 mg. The degradation reaction was characterised by the activation energy (Ea), enthalpy change (ΔH≠a), and entropy change (ΔS≠a). The degradation of RSV in acidic solution followed pseudo-first-order kinetics, with observed rate constants (kobs) of 2.63×10-3 s-1 and 3.80×10-3 s-1 for the 5 mg and 10 mg doses, respectively. The activation energy (Ea) was 102.1 kJ/mol and 101.8 kJ/mol for the 5 mg and 10 mg doses, respectively, indicating that the degradation process is moderately sensitive to temperature. The enthalpy change (ΔH≠a) for both doses was positive, with values of 92 kJ/mol and 102 kJ/mol for the 5 mg and 10 mg doses, respectively, indicating that the degradation reaction is endothermic, with the 5 mg dose requiring more significant heat input. The entropy change (ΔS≠a) for both doses was negative, with values of -0.219 kJ/(mol∙K) and -0.236 kJ/(mol∙K) for the 5 mg and 10 mg doses, respectively, indicating that the degradation process decreases the system's disorder, with the 5 mg dose having a more significant impact. The degradation of RSV in an alkaline medium was found to be a pseudo-first-order reaction, with observed rate constants ranging from 1.98×10-3 s-1 to 7.09×10-3 s-1, depending on the RSV concentration. The results suggest that higher RSV concentrations improve stability in alkaline conditions. These findings provide valuable insights into the stability of RSV under different pH conditions.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139251078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
(E)-3-(4-(tert-Butyl)Phenyl)-N-Isobutyl-2-Methylacrylamide Suppresses Adipogenesis in High-Fat-Fed Mice (E)-3-(4-(叔丁基)苯基)-N-异丁基-2-甲基丙烯酰胺能抑制高脂喂养小鼠的脂肪生成
Pub Date : 2023-11-21 DOI: 10.32383/appdr/171509
J. Hur, Sanghee Kim, Bo-ra Yoon, Guijae Yoo, In-Hae Choi, Ho-Young Park, Sang Yoon Choi
Obesity is caused by excessive adipogenesis and leads to metabolic diseases such as diabetes, hypertension, and degenerative arthritis. Therefore, there is an ever-increasing need to identify new anti-obesity compounds. In this study, the anti-obesity effects of (E)-3-(4-(tert-butyl)phenyl)-N-isobutyl-2-methylacrylamide (BPIMA) were evaluated using pre-adipocytes and a high-fat-fed C57BL/6J mouse model. As the results, BPIMA effectively inhibited adipocyte differentiation (64.3% at 40 μM) without exhibiting any cytotoxicity. Additionally, BPIMA decreased the protein levels of PPARγ, FAS, C/EBP, and SREBP in 3T3-L1 cells in a concentration-dependent manner. In C57BL/6J mice, a significant decrease in body weight, adipose tissue, and fatty liver was observed in the BPIMA-treated high-fat group compared to that observed in the vehicle-treated high-fat group; the serum levels of total cholesterol and glucose also significantly decreased in the BPIMA-treated high-fat group. Moreover, the weight and fat level of liver and serum AST, ALT activity in the BPIMA-treated high-fat group were similar to low fat diet-control group. These findings show that BPIMA may be a potential anti-obesity compound.
肥胖症是由过度的脂肪生成引起的,并导致糖尿病、高血压和退行性关节炎等代谢性疾病。因此,人们越来越需要找到新的抗肥胖化合物。本研究利用前脂肪细胞和高脂肪喂养的 C57BL/6J 小鼠模型,评估了 (E)-3-(4-(tert-butyl)phenyl)-N-isobutyl-2-methylacrylamide (BPIMA) 的抗肥胖作用。结果表明,BPIMA 能有效抑制脂肪细胞的分化(40 μM 时抑制率为 64.3%),且无任何细胞毒性。此外,BPIMA 还能以浓度依赖的方式降低 3T3-L1 细胞中 PPARγ、FAS、C/EBP 和 SREBP 的蛋白水平。在 C57BL/6J 小鼠中,观察到 BPIMA 处理的高脂肪组小鼠的体重、脂肪组织和脂肪肝水平比车辆处理的高脂肪组小鼠显著下降;BPIMA 处理的高脂肪组小鼠的血清总胆固醇和葡萄糖水平也显著下降。此外,BPIMA处理的高脂组肝重量和脂肪水平以及血清AST、ALT活性与低脂饮食对照组相似。这些研究结果表明,BPIMA可能是一种潜在的抗肥胖化合物。
{"title":"(E)-3-(4-(tert-Butyl)Phenyl)-N-Isobutyl-2-Methylacrylamide Suppresses Adipogenesis in High-Fat-Fed Mice","authors":"J. Hur, Sanghee Kim, Bo-ra Yoon, Guijae Yoo, In-Hae Choi, Ho-Young Park, Sang Yoon Choi","doi":"10.32383/appdr/171509","DOIUrl":"https://doi.org/10.32383/appdr/171509","url":null,"abstract":"Obesity is caused by excessive adipogenesis and leads to metabolic diseases such as diabetes, hypertension, and degenerative arthritis. Therefore, there is an ever-increasing need to identify new anti-obesity compounds. In this study, the anti-obesity effects of (E)-3-(4-(tert-butyl)phenyl)-N-isobutyl-2-methylacrylamide (BPIMA) were evaluated using pre-adipocytes and a high-fat-fed C57BL/6J mouse model. As the results, BPIMA effectively inhibited adipocyte differentiation (64.3% at 40 μM) without exhibiting any cytotoxicity. Additionally, BPIMA decreased the protein levels of PPARγ, FAS, C/EBP, and SREBP in 3T3-L1 cells in a concentration-dependent manner. In C57BL/6J mice, a significant decrease in body weight, adipose tissue, and fatty liver was observed in the BPIMA-treated high-fat group compared to that observed in the vehicle-treated high-fat group; the serum levels of total cholesterol and glucose also significantly decreased in the BPIMA-treated high-fat group. Moreover, the weight and fat level of liver and serum AST, ALT activity in the BPIMA-treated high-fat group were similar to low fat diet-control group. These findings show that BPIMA may be a potential anti-obesity compound.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139252053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antioxidant Activity of Polysaccharides From Natural Sources 天然来源多糖的抗氧化活性
Pub Date : 2023-11-21 DOI: 10.32383/appdr/173189
Tong Chen, Pan-Pan Wei, Mengyue Deng, Yuzhen Ding, Die Xia, Zijun Yan
Oxidative stress is associated with the development of many diseases, such as chronic inflammation, cardiovascular disease and cancer. Antioxidants can scavenge free radicals in the body, reduce the production of reactive oxygen species (ROS) and effectively prevent oxidative stress. Polysaccharide is a antioxidants that widely found in natural resources, which is a kind of high molecular polymer with antioxidant activity. It can prevent oxidative stress and play a role in disease prevention through various mechanisms. In this paper, the different types of polysaccharides were summarized, such as plant polysaccharides, algal polysaccharides, microbial polysaccharides and animal polysaccharides, and their antioxidant mechanism and application in the treatment of disease were also discussed. we hope this review can offer some theoretical basis and inspiration for the antioxidant activity study and application of polysaccharides from natural resources.
氧化应激与许多疾病的发生有关,如慢性炎症、心血管疾病和癌症。抗氧化剂可以清除体内自由基,减少活性氧(ROS)的产生,有效预防氧化应激。多糖是一种广泛存在于自然资源中的抗氧化剂,是一种具有抗氧化活性的高分子聚合物。它能通过多种机制防止氧化应激,在疾病预防中发挥作用。本文总结了植物多糖、藻类多糖、微生物多糖和动物多糖等不同类型的多糖,并探讨了它们的抗氧化机理和在疾病治疗中的应用,希望这篇综述能为自然资源中多糖的抗氧化活性研究和应用提供一些理论依据和启发。
{"title":"Antioxidant Activity of Polysaccharides From Natural Sources","authors":"Tong Chen, Pan-Pan Wei, Mengyue Deng, Yuzhen Ding, Die Xia, Zijun Yan","doi":"10.32383/appdr/173189","DOIUrl":"https://doi.org/10.32383/appdr/173189","url":null,"abstract":"Oxidative stress is associated with the development of many diseases, such as chronic inflammation, cardiovascular disease and cancer. Antioxidants can scavenge free radicals in the body, reduce the production of reactive oxygen species (ROS) and effectively prevent oxidative stress. Polysaccharide is a antioxidants that widely found in natural resources, which is a kind of high molecular polymer with antioxidant activity. It can prevent oxidative stress and play a role in disease prevention through various mechanisms. In this paper, the different types of polysaccharides were summarized, such as plant polysaccharides, algal polysaccharides, microbial polysaccharides and animal polysaccharides, and their antioxidant mechanism and application in the treatment of disease were also discussed. we hope this review can offer some theoretical basis and inspiration for the antioxidant activity study and application of polysaccharides from natural resources.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139250907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interaction of PUFAs and Doxorubicin: the Enhanced Toxicity in Breast Cancer Cells PUFA 与多柔比星的相互作用:增强乳腺癌细胞的毒性
Pub Date : 2023-11-21 DOI: 10.32383/appdr/171546
A. Zajdel, A. Wilczok
Doxorubicin (DOX) still remains one the most effective a clinical drug for breast cancer treatment. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the n-3 polyunsaturated fatty acids (PUFAs), exert pronounced toxicity against many types of cancers including breast cancer. That is why it was decided to investigate the mechanism of DOX and PUFAs toxicity on SK-BR-3 and MDA-MB-231 cells. The influence of DOX on the PUFAs oxidation and effect of DOX and EPA or DHA on cellular metabolic activity, viability, cytotoxicity, apoptosis and oxidative DNA damage in these cells were measured. DOX induced oxidation of the EPA and DHA. Toxicity of DOX and PUFAs towards breast cancer cells was associated with oxidative damage. These PUFAs reduced growth of the tested cells and caused their death. EPA and DHA potentiated DOX toxic effects through induction of oxidative DNA damage. The antitumor effect of PUFAs alone and combined with DOX strongly depended on induction of the oxidative stress that facilitated cell death. The observed changes of DOX toxicity induced by PUFAs suggest the possibility of their application in developing therapeutic anticancer strategies.
多柔比星(DOX)仍然是治疗乳腺癌最有效的临床药物之一。二十碳五烯酸(EPA)和二十二碳六烯酸(DHA),即 n-3 多不饱和脂肪酸(PUFAs),对包括乳腺癌在内的多种癌症具有明显的毒性。因此,我们决定研究 DOX 和 PUFA 对 SK-BR-3 和 MDA-MB-231 细胞的毒性机制。研究人员测定了 DOX 对 PUFAs 氧化的影响,以及 DOX 和 EPA 或 DHA 对这些细胞的代谢活性、存活率、细胞毒性、细胞凋亡和 DNA 氧化损伤的影响。DOX 诱导了 EPA 和 DHA 的氧化。DOX 和 PUFA 对乳腺癌细胞的毒性与氧化损伤有关。这些 PUFAs 可降低受测细胞的生长速度并导致其死亡。EPA 和 DHA 通过诱导氧化 DNA 损伤增强了 DOX 的毒性作用。PUFAs 单独或与 DOX 合用的抗肿瘤效果在很大程度上取决于氧化应激的诱导,而氧化应激可促进细胞死亡。观察到的 PUFAs 诱导的 DOX 毒性变化表明,它们有可能被应用于开发抗癌治疗策略。
{"title":"Interaction of PUFAs and Doxorubicin: the Enhanced Toxicity in Breast Cancer Cells","authors":"A. Zajdel, A. Wilczok","doi":"10.32383/appdr/171546","DOIUrl":"https://doi.org/10.32383/appdr/171546","url":null,"abstract":"Doxorubicin (DOX) still remains one the most effective a clinical drug for breast cancer treatment. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the n-3 polyunsaturated fatty acids (PUFAs), exert pronounced toxicity against many types of cancers including breast cancer. That is why it was decided to investigate the mechanism of DOX and PUFAs toxicity on SK-BR-3 and MDA-MB-231 cells. The influence of DOX on the PUFAs oxidation and effect of DOX and EPA or DHA on cellular metabolic activity, viability, cytotoxicity, apoptosis and oxidative DNA damage in these cells were measured. DOX induced oxidation of the EPA and DHA. Toxicity of DOX and PUFAs towards breast cancer cells was associated with oxidative damage. These PUFAs reduced growth of the tested cells and caused their death. EPA and DHA potentiated DOX toxic effects through induction of oxidative DNA damage. The antitumor effect of PUFAs alone and combined with DOX strongly depended on induction of the oxidative stress that facilitated cell death. The observed changes of DOX toxicity induced by PUFAs suggest the possibility of their application in developing therapeutic anticancer strategies.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139253776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypoglycemic Effect of Betulin in Rats With Experimental Diabetes 白桦脂素对实验性糖尿病大鼠的降血糖作用
Pub Date : 2023-11-21 DOI: 10.32383/appdr/172620
Agnieszka Zakrzeska, P. Kitlas, A. Shlyahtun, Natalia Szymańska, Ryszard Jabłoński, M. Tomulewicz
Betulin is natural pentacyclic triterpenoids lupane-structure, which shows a wide range of biological activity, including possibly hypoglycemic effects. Diabetes mellitus is a metabolic disease, accompanied by chronic hyperglycemia caused by absolute or relative insulin deficiency. The main effective drug in the treatment of type 1 diabetes is insulin injections. In the case of type 2 diabetes, it is an adjuvant therapy. To purpose of this study was to show hypoglycemic action of betulin in a model of experimentally induced diabetes in rats. For the induction of diabetes, alloxan at a dose of 170 mg/kg, i.p. was used. The hypoglycemic effect of betulin was evaluated using doses of 50 and 100 mg/kg/day for 30 days. The activity of glucose metabolism enzymes: liver glycogen phosphorylase, hexokinase and liver and skeletal muscle phosphofructokinase in rats, glucose-6-phosphate dehydrogenase (DG-6-P) of the liver was also evaluated. Betulin in a dose-dependent manner normalized of glycemia, increased the basal insulin concentration in the blood serum, increased the activity of carbohydrate metabolizing enzymes and on the gene expression profile of enzymes involved in carbohydrate metabolism. Betulin also significant improved the morphology of the pancreas. In particular, there was an increase in the area of the islands, their diameter, an increase in the number of β cells in the composition of the islands. We conclude that betulin has hypoglycemic properties, improving glycemia and carbohydrate metabolizing enzymes and pancreatic morphology.
白桦脂是一种天然的五环三萜类羽扇豆结构的化合物,具有广泛的生物活性,包括可能的降血糖作用。糖尿病是一种代谢性疾病,由胰岛素绝对或相对缺乏引起的慢性高血糖伴随。治疗 1 型糖尿病的主要有效药物是注射胰岛素。对于 2 型糖尿病,胰岛素是一种辅助疗法。本研究的目的是在大鼠实验性糖尿病模型中显示白桦脂的降血糖作用。诱导糖尿病时,使用了 170 毫克/千克剂量的阿脲,静脉注射。评估了白桦脂的降血糖作用,剂量分别为 50 毫克/公斤和 100 毫克/公斤/天,持续 30 天。还评估了葡萄糖代谢酶的活性:大鼠肝糖原磷酸化酶、己糖激酶、肝脏和骨骼肌磷酸果糖激酶、肝脏葡萄糖-6-磷酸脱氢酶(DG-6-P)。桦木醇以剂量依赖的方式使血糖正常化,增加了血清中的基础胰岛素浓度,提高了碳水化合物代谢酶的活性,并改变了碳水化合物代谢酶的基因表达谱。白桦脂还明显改善了胰腺的形态。特别是,胰岛的面积和直径都有所增加,胰岛组成中的β细胞数量也有所增加。我们的结论是,白桦脂具有降血糖作用,能改善血糖、碳水化合物代谢酶和胰腺形态。
{"title":"Hypoglycemic Effect of Betulin in Rats With Experimental Diabetes","authors":"Agnieszka Zakrzeska, P. Kitlas, A. Shlyahtun, Natalia Szymańska, Ryszard Jabłoński, M. Tomulewicz","doi":"10.32383/appdr/172620","DOIUrl":"https://doi.org/10.32383/appdr/172620","url":null,"abstract":"Betulin is natural pentacyclic triterpenoids lupane-structure, which shows a wide range of biological activity, including possibly hypoglycemic effects. Diabetes mellitus is a metabolic disease, accompanied by chronic hyperglycemia caused by absolute or relative insulin deficiency. The main effective drug in the treatment of type 1 diabetes is insulin injections. In the case of type 2 diabetes, it is an adjuvant therapy. To purpose of this study was to show hypoglycemic action of betulin in a model of experimentally induced diabetes in rats. For the induction of diabetes, alloxan at a dose of 170 mg/kg, i.p. was used. The hypoglycemic effect of betulin was evaluated using doses of 50 and 100 mg/kg/day for 30 days. The activity of glucose metabolism enzymes: liver glycogen phosphorylase, hexokinase and liver and skeletal muscle phosphofructokinase in rats, glucose-6-phosphate dehydrogenase (DG-6-P) of the liver was also evaluated. Betulin in a dose-dependent manner normalized of glycemia, increased the basal insulin concentration in the blood serum, increased the activity of carbohydrate metabolizing enzymes and on the gene expression profile of enzymes involved in carbohydrate metabolism. Betulin also significant improved the morphology of the pancreas. In particular, there was an increase in the area of the islands, their diameter, an increase in the number of β cells in the composition of the islands. We conclude that betulin has hypoglycemic properties, improving glycemia and carbohydrate metabolizing enzymes and pancreatic morphology.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139251045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Compatibility Study of Ketoprofen With Selected Excipients Used in Solid Dosage Forms: Experimental Design Approach 酮洛芬与固体制剂中使用的某些辅料的相容性研究:实验设计方法
Pub Date : 2023-11-21 DOI: 10.32383/appdr/172622
Joanna Ronowicz-Pilarczyk
A good understanding of the physico-chemical characteristics of a drug substance and excipients is necessary to obtain a safe and effective drug dosage form. Based on the current recommendations of the regulatory agencies (EMA, FDA) regarding the implementation of the Quality by Design concept at the drug product development stage, this article is focused on the application of the experimental design approach at the preformulation studies. The purpose of this work was the implementation of experimental design methodology in a compatibility study between ketoprofen (non-steroidal anti-inflammatory drug) and selected solid dosage forms excipients. The fractional factorial design was used to generate a matrix of multi-component mixtures of ketoprofen and selected excipients. In order to accelerate any chemical incompatibilities, the received mixtures were exposed to elevated temperature and humidity (60°C/75% RH) in a climate chamber for 3 weeks. The ketoprofen-excipients compatibility was studied by means of the RP-HPLC method. It was confirmed that the type of disintegrant had a strong impact on ketoprofen degradation. The incompatibility in mixtures of ketoprofen with sodium starch glycolate was indicated. According to literature data, it may be the result of a decrease in crystallinity and thus a decrease in the stability of ketoprofen in the presence of sodium starch glycolate. The effects of the other types of excipients were statistically insignificant (p > 0.05). The applied experimental design methodology allowed for a rational selection of optimal excipients and thus, this approach may support significantly decision-making in the pharmaceutical industry.
要获得安全有效的药物剂型,就必须充分了解药物物质和辅料的物理化学特性。根据目前监管机构(EMA、FDA)关于在药物产品开发阶段实施 "设计质量 "理念的建议,本文重点介绍了实验设计方法在制剂前研究中的应用。这项工作的目的是在酮洛芬(非甾体抗炎药)与选定固体制剂辅料之间的相容性研究中实施实验设计方法。采用分数因子设计法生成酮洛芬和选定辅料的多组分混合物矩阵。为了加速化学不相容性,将收到的混合物在恒温恒湿(60°C/75% RH)环境中暴露 3 周。采用 RP-HPLC 方法研究了酮洛芬与辅料的相容性。结果表明,崩解剂的类型对酮洛芬的降解有很大影响。结果表明,酮洛芬与淀粉乙醇酸钠的混合物不相容。根据文献数据,这可能是由于结晶度降低,从而降低了酮洛芬在淀粉乙醇酸钠存在下的稳定性。其他类型辅料的影响在统计学上不显著(p > 0.05)。应用实验设计方法可以合理选择最佳辅料,因此,这种方法可以为制药业的决策提供重要支持。
{"title":"Compatibility Study of Ketoprofen With Selected Excipients Used in Solid Dosage Forms: Experimental Design Approach","authors":"Joanna Ronowicz-Pilarczyk","doi":"10.32383/appdr/172622","DOIUrl":"https://doi.org/10.32383/appdr/172622","url":null,"abstract":"A good understanding of the physico-chemical characteristics of a drug substance and excipients is necessary to obtain a safe and effective drug dosage form. Based on the current recommendations of the regulatory agencies (EMA, FDA) regarding the implementation of the Quality by Design concept at the drug product development stage, this article is focused on the application of the experimental design approach at the preformulation studies. The purpose of this work was the implementation of experimental design methodology in a compatibility study between ketoprofen (non-steroidal anti-inflammatory drug) and selected solid dosage forms excipients. The fractional factorial design was used to generate a matrix of multi-component mixtures of ketoprofen and selected excipients. In order to accelerate any chemical incompatibilities, the received mixtures were exposed to elevated temperature and humidity (60°C/75% RH) in a climate chamber for 3 weeks. The ketoprofen-excipients compatibility was studied by means of the RP-HPLC method. It was confirmed that the type of disintegrant had a strong impact on ketoprofen degradation. The incompatibility in mixtures of ketoprofen with sodium starch glycolate was indicated. According to literature data, it may be the result of a decrease in crystallinity and thus a decrease in the stability of ketoprofen in the presence of sodium starch glycolate. The effects of the other types of excipients were statistically insignificant (p > 0.05). The applied experimental design methodology allowed for a rational selection of optimal excipients and thus, this approach may support significantly decision-making in the pharmaceutical industry.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139252354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Poloniae Pharmaceutica - Drug Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1